Selected data models

You must log in to select data models for download or further analysis.

12 Search results.
Relevance Rating New first Old first

Eligibility DRKS00005506 NCT00964977 Oropharyngeal Cancer - Eligibility

- 4/17/14 - 1 form, 2 itemgroups, 13 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00964977

Initial Evaluation Oropharyngeal Cancer RTOG 1016 I1NCT01302834

- 8/4/15 - 1 form, 11 itemgroups, 85 items, 1 language
Itemgroups: Header Module, Patient demographics, Tumor Measurements At Presentation, Basis of Diagnosis, Laboratory Values, Primary Site, Staging, PRIOR TREATMENT, SEVERE ACTIVE COMORBIDITIES, Protocol Specific Adverse Event Evaluation: Use the CTC AE version 4 (MedDRA 12) to code all events., Footer Module
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=94417A43-2D71-18EF-E040-BB89AD432749

NCT01302834 RTOG 1016 TF: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Treatment Summary Form

- 7/8/15 - 1 form, 12 itemgroups, 67 items, 1 language
Itemgroups: RTOG clinical trial administrative data, Summary of Systemic Treatment, ARM 1 ONLY - DAY 1, DAY 22, Header, ARM 2 ONLY - WEEK 1 - INITIAL DOSE, WEEK 2-8, Non-Protocol Therapy, Tube feeding, Protocol Specific Adverse Event Evaluation: Use the CTC AE version 4 (MedDRA 12) to code all events., New or continuing adverse events, Comments
NCT01302834 RTOG 1016 TF: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Treatment Summary Form Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9418B248-C31D-807C-E040-BB89AD431782

NCT01302834 RTOG 1016 F0: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Follow-Up Form

- 7/8/15 - 1 form, 9 itemgroups, 44 items, 1 language
Itemgroups: Header Module, Vital status, Tumor Measurements At Presentation, RECURRENCE OR PROGRESSION, New primary cancer, NON-PROTOCOL THERAPY, Protocol Specific Adverse Event Evaluation, New or continuing adverse events, Comments
NCT01302834 RTOG 1016 F0: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Follow-Up Form Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9550D538-F61F-EAB4-E040-BB89AD4377BB

NCT01302834 RTOG 1016 F1: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Follow-Up Form

- 7/8/15 - 1 form, 8 itemgroups, 44 items, 1 language
Itemgroups: RTOG clinical trial administrative data, Patient status assessment, RECURRENCE OR PROGRESSION, New primary cancer, Non-protocol Therapy, Protocol Specific Adverse Event Evaluation, New or continuing adverse events, Comments
NCT01302834 RTOG 1016 F1: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Follow-Up Form Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=944181D6-4EF9-82FB-E040-BB89AD43799B

NCT01302834 Quality of Life - RTOG 1016 PQ: Radiation Therapy Oncology Group Phase III Head and Neck Cancer PRO-CTCAE Assessment - 3159842v1.0 - RTOG 1016 PQ: Radiation Therapy Oncology Group Phase III Head and Neck Cancer PRO-CTCAE Assessment

- 1/9/15 - 1 form, 6 itemgroups, 51 items, 1 language
Itemgroups: Header Module, PRO-CTCAE Assessment, PRO-CTCAE Assessment (cont.1), PRO-CTCAE Assessment (cont.2), PRO-CTCAE Assessment (cont.3) , PRO-CTCAE Assessment (cont.4)
RTOG 1016 PQ: Radiation Therapy Oncology Group Phase III Head and Neck Cancer PRO-CTCAE Assessment Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=95331A4F-A6A2-25A3-E040-BB89AD432C5C

NCT01302834 Quality of Life - RTOG 1016 QN: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Hearing Handicap Inventory for Adults (HHIA-S) - 3183758v1.0 - RTOG 1016 QN: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Hearing Handicap Inventory for Adults (HHIA-S)

- 1/9/15 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Header Module, HEARING HANDICAP INVENTORY FOR ADULTS SCREENING QUESTIONNAIRE (NEWMAENT AL., 1990; NEWMAENT AL., 1991)
RTOG 1016 QN: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Hearing Handicap Inventory for Adults (HHIA-S) Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9A132BA5-9085-FFE2-E040-BB89AD43727A

Eligibility Dysphagia NCT01748942

- 11/29/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01748942

Eligibility Carcinoma NCT00728130

- 11/10/17 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00728130

Radiation in Low-Risk HPV Squamous Cell Carcinoma NCT01530997 - Eligibility Criteria

- 9/17/21 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
De-intensification of Radiation and Chemotherapy for Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01530997 The purpose of this research study is to learn about the effectiveness of using lower-intensity radiation and chemotherapy to treat human papillomavirus (HPV) associated low-risk oropharyngeal and/or unknown primary squamous cell carcinomas of the head and neck. The cure rate for this type of cancer is estimated to be high, > 90%. The standard treatment for this cancer is 7 weeks of radiation with 3 high doses of cisplatin. Sometimes surgery is performed afterwards. This standard regimen causes a lot of side effects and long term complications. This study is evaluating whether a lower dose of radiation and chemotherapy may provide a similar cure rate as the longer, more intensive standard regimen. Patients in this study will receive 1 less week of radiation and a lower weekly dose of chemotherapy followed by a limited surgical evaluation.

Eligibility HPV Positive Oropharyngeal Squamous Cell Carcinoma NCT01855451

- 3/2/20 - 1 form, 2 itemgroups, 34 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01855451

Eligibility Early-Stage Squamous Cell Carcinoma of the Oropharynx NCT01590355

- 12/3/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR); ODM derived from: https://clinicaltrials.gov/show/NCT01590355

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial